Abstract
The gut bacteria producing metabolites like short-chain fatty acids (SCFAs; e.g., acetate, propionate and butyrate), are frequently reduced in Patients with diabetes, obesity, autoimmune disorders, and cancers. Hence, microbiome modulators such as probiotics may be helpful in maintaining or even restoring normal gut microbiome composition to benefit host health. Herein, we developed a human-origin probiotic cocktail with the ability to modulate gut microbiota to increase native SCFA production. Following a robust protocol of isolation, characterization and safety validation of infant gut-origin Lactobacillus and Enterococcus strains with probiotic attributes (tolerance to simulated gastric and intestinal conditions, adherence to intestinal epithelial cells, absence of potential virulence genes, cell-surface hydrophobicity, and susceptibility to common antibiotics), we select 10 strains (5 from each genera) out of total 321 isolates. A single dose (oral gavage) as well as 5 consecutive doses of this 10-strain probiotic cocktail in mice modulates gut microbiome and increases SCFA production (particularly propionate and butyrate). Inoculation of these probiotics in human feces also increases SCFA production along with microbiome modulation. Results indicate that human-origin probiotic lactobacilli and enterococci could ameliorate gut microbiome dysbiosis and hence may prove to be a potential therapy for diseases involving reduced SCFAs production in the gut.
Highlights
IntroductionThe human gastrointestinal tract harbors a highly diverse and complex community of 1013 to 1014 microorganisms (collectively known as the gut microbiome) living in a symbiotic manner[1]
The human gastrointestinal tract harbors a highly diverse and complex community of 1013 to 1014 microorganisms living in a symbiotic manner[1]
We develop a consortium of 10 probiotic Lactobacillus and Enterococcus strains isolated from healthy infants’ gut, and demonstrate their effects on the gut microbiome composition and SCFAs levels in-vivo in healthy mice as well as ex-vivo in human feces
Summary
The human gastrointestinal tract harbors a highly diverse and complex community of 1013 to 1014 microorganisms (collectively known as the gut microbiome) living in a symbiotic manner[1]. Specific probiotic strains can effectively prevent or treat diseases including inflammatory bowel disease[17], necrotizing enterocolitis[18], obesity/type 2 diabetes[19], and autoimmunity[20] in both rodent models and humans; the mechanisms underlying such benefits are not understood These reports have led to an extensive demand for probiotic supplements over the last decade, thereby prompting a massive increase in the development of new probiotic products for the consumer market. Probiotics are rapidly emerging as novel and natural therapeutic options; isolation and characterization of new strains with well-characterized mechanisms of action remain of considerable interest and importance In this context, we develop a consortium of 10 probiotic Lactobacillus and Enterococcus strains isolated from healthy infants’ gut, and demonstrate their effects on the gut microbiome composition and SCFAs levels in-vivo in healthy mice as well as ex-vivo in human feces
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.